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For many years, the brain has been the primary focus for research on eating behavior. More
recently, the discovery of the endocannabinoids (EC) and the endocannabinoid system
(ECS), as well as the characterization of its actions on appetite and metabolism, has
provided greater insight on the brain and food intake.The purpose of this review is to explain
the actions of EC in the brain and other organs as well as their precursor polyunsaturated
fatty acids (PUFA) that are converted to these endogenous ligands. The binding of the EC
to the cannabinoid receptors in the brain stimulates food intake, and the ECS participates
in systemic macronutrient metabolism where the gastrointestinal system, liver, muscle,
and adipose are involved. The EC are biosynthesized from two distinct families of dietary
PUFA, namely the n-6 and n-3. Based on their biochemistry, these PUFA are well known
to exert considerable physiological and health-promoting actions. However, little is known
about how these different families of PUFA compete as precursor ligands of cannabinoid
receptors to stimulate appetite or perhaps down-regulate the ECS to amend food intake
and prevent or control obesity. The goal of this review is to assess the current available
research on ECS and food intake, suggest research that may improve the complications
associated with obesity and diabetes by dietary PUFA intervention, and further reveal
mechanisms to elucidate the relationships between substrate for EC synthesis, ligand
actions on receptors, and the physiological consequences of the ECS. Dietary PUFA are
lifestyle factors that could potentially curb eating behavior, which may translate to changes
in macronutrient metabolism, systemically and in muscle, beneﬁting health overall.
Keywords: food intake behavior, endocannabinoids, polyunsaturated fatty acids, appetite, cannabinoid receptors,
brain and neuronal function
INTRODUCTION
Decades ago, it was recognized that macronutrient expenditure
and maintenance of dietary intake are controlled by complex
physiological processes involving endocrine, neurological, and
behavioral factors (Mayer and Thomas, 1967). More recently, the
ECSwas found to be integral in the control of food intake and a tar-
get to mitigate obesity (Cota, 2007). The cannabinoid receptors of
this systemare present in large numbers in the brain, and their acti-
vation by endogenous agonists, called EC, has revealed yet another
aspect of the neuroendocrine system’s participation in caloric
intake (Mackie, 2008; Viveros et al., 2008). Furthermore, stud-
ies using pharmacological antagonists of the cannabis receptors in
the brain have demonstratedmarked improvements in weight loss
and appetite control in humans but with undesirable side effects
that include heart disease and depression (Di Marzo and Despres,
2009). The ﬁrst discovered EC were found to be biosynthesized
from PUFA of the n-6 family, however, those derived from the
Abbreviations: AA, arachidonic acid; AEA, arachidonylethanolamide; 2-AG, 2-
arachidonoylglycerol; DHA, docosahexaenoic acid; EC, endocannabinoids; ECS,
endocannabinoid system; EPA, eicosapentaenoic acid; FAAH, fatty acid amide
hydrolase;MAGL,monoacylglycerol lipase; NAE,N-acylethanolamine; NAPE-PLD,
p N-acyl phosphatidylethanolamine selective phospholipase D; PUFA, polyunsatu-
rated fatty acids.
n-3 PUFA family have shown the potential of a dietary approach
to modulate activation of the cannabinoid receptors to diminish
food intake and downstream events that reduce macronutrient
metabolism directed toward fat accumulation (Naughton et al.,
2013). Indirect evidence to support this premise comes from stud-
ies in n-3 PUFA deﬁcient-mice which abolished EC mediated
neuronal functions (Lafourcade et al., 2011) andwhere feeding n-3
PUFA decreased the levels of the n-6 PUFA derived EC (Watanabe
et al., 2003; Alvheim et al., 2012). The n-3 PUFA may lower acti-
vation of cannabinoid receptors, thereby attenuating food intake
(Watkins et al., 2010; Kim et al., 2013).
The ECS includes both synaptic and peripheral signaling func-
tions, and the cannabinoid receptors are found inmanyorgans and
tissues besides the nervous system (Mackie, 2008). Cannabinoid
receptors are G protein-coupled receptors that upon activation,
lead to multiple complex signaling pathways (Lafourcade et al.,
2011). AEA and 2-AG, both derived from (20:4n-6 an n-6 PUFA),
are the two most abundant endogenous EC for the cannabi-
noid receptors CB1 and CB2 (Bisogno et al., 1999; Bosier et al.,
2010). However, other EC have been identiﬁed which include
those biosynthesized from n-3 PUFA, such as eicosapentaenoyl
ethanolamide from eicosapentaenoic acid (EPA or 20:5n-3) and
docosahexaenoyl ethanolamide from docosahexaenoic acid (DHA
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or 22:6n-3; Rossmeisl et al., 2012; Kimet al.,2014a). Binding afﬁni-
ties differ between the various EC ligands for the cannabinoid
receptors, and as such, result in varying degrees of activation of
the receptor and downstream effects (Mackie, 2008), which, in the
case of the central nervous system (CNS), includes blocking of
neurotransmitter release from the presynaptic neuron (Okamoto
et al., 2004). The binding afﬁnities of the EC derived from either
EPA or DHA toward cannabinoid receptors are shown to be com-
paratively weaker than the AA-derived EC (Brown et al., 2010).
In cells and tissues, a dynamic competition exists in the bio-
chemistry of the PUFA families, and recently, their actions on
ECS gene expression in both humans and rodents have varied
(Watkins et al., 2010; Kim et al., 2013). Examples of how PUFA
and EC change the expression of ECS-related genes have been
reported in C2C12 myoblast cultures (Kim et al., 2014a) and in
mice (Hutchins-Wiese et al., 2012). In studies with rodents, the
consumption of dietary lipids varying in the amounts of n-6 and
n-3 PUFA as well as monounsaturated fatty acids is now believed
to be one approach to control appetite and obesity by chang-
ing endogenous levels of EC and subsequent receptor activation
(Naughton et al., 2013).
During development, measurable increases in the expression
of cannabinoid receptors (mRNA and protein) and circulating
levels of EC have been reported, along with receptor binding
in the fetal and early post-natal brains of rodents (Berrendero
et al., 1999). Along with aging, it is suggested that a decrease in
ECS activity is associated with a decline in neuroprotective reg-
ulation in the brain of rodents (Bilkei-Gorzo, 2012). Evidence
supporting the neuroprotective beneﬁts conferred by ECS inter-
vention is scarce but growing (Goncalves et al., 2008; Marchalant
et al., 2008, 2009). While the means of protection are a result
of pharmacological intervention on the cannabinoid receptors,
aging and environmental factors, such as dietary n-6 PUFA, may
provide a protective mechanism to maintain circulating levels
of EC that would offset the decline of biosynthetic enzyme lev-
els for EC synthesis. However, at the same time, the n-3 PUFA
may help to minimize overstimulation of the ECS during obesity
to reduce the n-6 PUFA derived EC (Kim et al., 2014b). Thus,
dietary PUFA studies are of great research interest to better under-
stand eating behavior and excess caloric intake in the adolescent
and young adult populations, as well as suppressed appetites in
older adults. The aim of this research is to determine how spe-
ciﬁc families of dietary PUFA alter EC levels, receptor excitability,
and signaling to improve health outcomes throughout the life
cycle.
Herein, we describe the ECS and how it is integrated in the bio-
logical control of food intake; maintenance of the ECS; actions
of PUFA on genes of the ECS; relationships between muscle,
adipose, and liver; and aging. Throughout this review, we will
suggest research to further elucidate the interactions between
PUFA and the ECS and recommend approaches to advance the
understanding of how EC and receptors function in the body.
OVERVIEW OF THE ENDOCANNABINOID SYSTEM IN THE
BRAIN AND PERIPHERAL ORGANS
The functional components of the ECS are the cannabinoid recep-
tors, biosynthesis and degradation enzymes of the EC ligands, and
their signaling pathways (Murray et al., 2007). Although the brain
and CNS exhibit all of these attributes of the ECS (Mackie, 2008),
the components of this system have also been shown to be present
and active in several organs, tissues, and cells (Vettor et al., 2008;
De Petrocellis and Di Marzo, 2009). In the late 1980s the central
receptor for the psychotropic component of cannabis, tetrahy-
drocannabinol, was identiﬁed as cannabinoid receptor 1 (CB1;
Devane et al., 1988), and it was later cloned in 1990 by Matsuda
et al. (1990). Endogenous agonists for CB1 and the predominantly
localized peripheral cannabinoid receptor, CB2, were also iden-
tiﬁed in the early and mid-1990s (Mechoulam et al., 1995). AEA
was ﬁrst discovered as a cannabinoid ligand, followed by 2-AG;
these fatty acid derived compounds are made on demand and act
locally in a paracrine or autocrine fashion. CB1 has since been
identiﬁed to be localized on numerous peripheral tissues such
as adipose, liver, and muscle (Kim et al., 2013). CB2 was ﬁrst
identiﬁed in immunocompetent cells and has since been iden-
tiﬁed in various peripheral organs (i.e., bone, muscle, heart)
and the CNS, albeit to a lesser degree than CB1 expression.
The cannabinoid receptors are Gi/o protein-coupled receptors
and share 44% overall identity (Howlett, 2005). Upon activa-
tion, a signaling cascade occurs and results in the inhibition
of adenylyl cyclase, cAMP, and protein kinase A. The signaling
pathways of the ECS are recognized as a target for therapeutic
applications (Bosier et al., 2010), but the complex relationships
between the endogenous ligands, receptors, and signaling are
poorly understood.
The ECS signaling pathways are multifaceted because the many
endogenous ligands, including those derived from the n-6 and n-3
PUFA families, result in varying degrees of receptor activation and
involve different intracellular transduction pathways to inﬂuence
numerous physiological functions (Bosier et al., 2010). The mod-
iﬁcation of receptor activation by the different endogenous and
exogenous ligands selectively directs the downstreamactions of the
ECS in vivo. At present, the actions of the multitude of ligands on
the ECS are not well described in the literature. Potentially, mod-
iﬁcation of the ECS by endogenous ligands derived from dietary
PUFAmay be a means to blunt food intake and alter physiological
processes to reduce obesity and improve skeletal muscle response
to glucose and insulin sensitivity (Kim et al., 2013, 2014a). These
relationships are now under investigation in rodents and humans
(Viveros et al., 2008); however, there are few clinical published
studies (McPartland et al., 2014). Adequate amounts of dietary n-
3 PUFA are necessary for proper cannabinoid signaling, and the
long chain n-3 PUFA, both DHA and EPA, moderate the cellu-
lar levels of AEA and 2-AG, thus acting as a means to alter ECS
signaling to reduce over stimulation of signaling and its nega-
tive consequences on health, such as obesity (Kim et al., 2013;
McPartland et al., 2014).
Additional downstream signaling pathways resulting from the
ECS include extracellular receptor kinase, mitogen activated pro-
tein kinase, c-Jun N-terminal kinases, and c-fos (Wartmann et al.,
1995; Howlett, 2005). CB1 activation in neurons and other cra-
nial tissues is responsible for inhibition of intracellular cAMP,
dephosphorylation of potassium and calcium ion channels, and
increased intracellular free Ca2+ (Howlett, 2005). CB2 activation
in immune cells is generally considered anti-inﬂammatory and
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immunomodulatory (Han et al., 2009; Hao et al., 2010). AEA acts
as a partial CB1 agonist and aweakCB2 agonist, while 2-AG is a full
CB1 and CB2 agonist (Bisogno et al., 2005). Two additional recep-
tors, GPR55 (Ryberg et al., 2007) and transient receptor potential
vanilloid type 1 (Ross, 2003) are also activated by AEA; although,
their interactions with the ECS are currently under investigation.
The next research area for the ECS must include character-
ization of the downstream actions and should also include the
relationships of related substrates, such as the ligands for the EC
receptors and those that can be used by cyclooxygenase (Kim and
Watkins, 2014). This research will have implications on brain
functions, inﬂammatory status, and disease pathogenesis. The
physiological aspects of this research have implications in obe-
sity and insulin resistance, but with regards to food intake, such
research can integrate the role of the ECS in systemic macronu-
trient metabolism and fat accretion. The ECS has some impact
on directing systemic macronutrient metabolism, which involves
the intestinal tract, liver, muscle, and adipose (Viveros et al., 2008;
Kim et al., 2013). Hence, the interest in the ECS on food intake and
energy balance is of vital importance to human health (Di Marzo
and Matias, 2005; Tibirica, 2010).
ENDOCANNABINOID BIOSYNTHESIS, DEGRADATION AND
THE BRAIN
Arachidonylethanolamide and 2-AG are biosynthesized from AA
in the phospholipid membrane and are the two most studied
endogenous ligands for the cannabinoid receptors. AEA is synthe-
sized from AA in the sn-1 position on phospholipids and is found
at pmol/g concentrations in tissues, whereas 2-AG is formed from
AA in the sn-2 position. AA is more abundant in the sn-2 posi-
tion of the phospholipids in the cell membrane, leading to higher
tissue concentrations of 2-AG (ng/g range) than AEA (Bab et al.,
2009). Currently, there are three known routes of AEA formation
fromAA. The two step synthesis by NAPE-PLD is the major path-
way, where AA is ﬁrst cleaved as a phosphatidylethanolamine by
an acyltransferase to form NAPE and then the NAE is released
from NAPE by a selective PLD (Okamoto et al., 2004). When
AA is the starting substrate, the released NAE is AEA. NAE has
been previously found to function as a signaling molecule in var-
ious tissues, primarily in the CNS (Schmid, 2000). Another route
of synthesis is via hydrolysis of NAPE from phospholipase C,
forming an N-arachidonoylethanolamine phosphate which can
then be hydrolyzed by a phosphatase to form AEA. Synthesis of
AEA can also be achieved by a condensation pathway where a
FAAH works in reverse, starting with AA and ethanolamine. As
for the synthesis of 2-AG, various pathways have been charac-
terized (Sugiura et al., 1995). For example, phosphatidylinositol
(PI) can be hydrolyzed by phospholipase A, forming a lysophos-
phatidylinositol which is then hydrolyzed by phospholipase C to
form 2-AG. Additionally, 2-AG can also be produced in response
to a stimulus, such as ionomycin, in which PI is hydrolyzed by
phospholipase C forming triacylglycerol (DAG) and hydrolyzed
once more by DAG lipase (DAGL). A third mechanism in form-
ing 2-AG is via conversion of 2-arachidonoyl lysophosphatidic
acid to 2-AG, which is accomplished by monoacylglycerol kinase.
Degradation of AEA, and to a lesser degree 2-AG, occurs by FAAH
to produce AA and an ethanolamide. The degradation of 2-AG
occurs by MAGL to form AA and monoglycerol (Sugiura et al.,
2002).
Previously,NAPE-PLDwas shown to be expressed by particular
populations of neurons in the brain, speciﬁcally targeting axon
and axon terminals to mediate anterograde signaling at synapses
(Egertova et al., 2008). This is evident in the observations where
AEA acts as a retrograde messenger to bind to the axonal terminal
of presynaptic neurons in the hippocampus (Wilson and Nicoll,
2001; Alger, 2002).
Agonists and inverse agonist actions on the cannabinoid recep-
tors result in high to low responses, compared to basal cellular
levels (Mackie, 2008). The in vitro response is dependent upon
the binding afﬁnity of the ligand to the cannabinoid receptor, the
activation of the receptor, and the resulting downstream actions
through the signaling pathways, which include gene expres-
sion; however, these are not well characterized in vivo (Bosier
et al., 2010). What is clear is that the ECS in the brain controls
food intake via the hypothalamus and limbic systems, where
activation of cannabinoid receptors induces fat accumulation
(Viveros et al., 2008). In addition, activation of receptors may
divert macronutrient metabolism toward lipid synthesis in adi-
pose (Osei-Hyiaman et al., 2005; Bluher et al., 2006). Moreover,
dietary PUFA directly affect the concentration of speciﬁc EC in
blood and tissues in vivo (Artmann et al., 2008; Wood et al., 2010;
Kim et al., 2014b). The effects of dietary n-6 PUFA on the enzymes
of synthesis and degradation of the EC is worthy of investigation
in vivo and in cell cultures (Kim et al., 2014a). Conversely, sufﬁ-
cient evidence supports the need to conduct human studies that
examine the full extent in which n-3 PUFA derived EC alter the
ECS in health and in controlling obesity and insulin resistance
(McPartland et al., 2014).
ENDOCANNABINOIDS, THE GASTROINTESTINAL TRACT,
AND CONTROL OF FOOD INTAKE
The ECS is well known to be involved in the regulation of appetite,
food intake, and energy metabolism (Tibirica, 2010; Kim et al.,
2011). Initially, it was thought that the effects of EC were local-
ized in the CNS. The EC can act as neurotransmitters between
neurons in various regions of the brain (Bermudez-Silva et al.,
2012). They behave as retrograde messengers on CB1 at presy-
naptic glutamatergic terminals in the hypothalamus, resulting in
the inhibition of the release of the excitatory neurotransmitter
glutamate and leading to an overall suppressive effect on neuroen-
docrine function (Di et al., 2003). One of the major consequences
of ECS action on the hypothalamus is affecting neuroendocrine
functioning (Harmon and Aliapoulios, 1972). From an evolution-
arily perspective, the primary physiological function of the ECS
appears to shift energy balance toward energy storage (Piazza et al.,
2007), and thus, can lead to fat accumulation. While the neces-
sity for the ECS was more obvious for our hunter and gatherer
ancestors when food supply was not guaranteed, the technological
advances of today provide greater stability in regards to food avail-
ability. However, today this is more of a disadvantage with regard
to being overweight and obese. An excessive food supply and an
overactivation of CB1 can lead to overeating and a susceptibility
of metabolism to favor energy storage and obesity (Piazza et al.,
2007).
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Stimulation in the CNS of CB1 by AEA and 2-AG increases
hyperphagia, and the response is a higher food intake (Williams
and Kirkham, 1999; Kirkham et al., 2002). The ECS controls food
intake in two ways: (1) reinforces the motivation to ﬁnd and con-
sume food with high incentive value, and (2) induces appetite by
regulating levels and actions of orexigenic and anorectic media-
tors (Di Marzo and Matias, 2005; Monteleone et al., 2005). The
hyperphagic properties of EC were reported in Williams and
Kirkham (1999) when AEA was injected peripherally to stimu-
late feeding behavior and overeating in satiated rats, an effect
that was attenuated by selectively blocking CB1 with the antag-
onist SR141716. AEA caused a modest hyperphagic response
that appeared over a longer time course, as compared to 9-
THC (Williams and Kirkham, 1999). Injection of 2-AG into the
nucleus accumbens shell, an area of the basal forebrain associ-
ated with appetite stimulation, induced eating in rats (Kirkham
et al., 2002). This increase in food intake from 2-AG treatment
was prevented by pre-treatment with the antagonist SR141716,
while the CB2 antagonist SR144258 had no effect; thus, it
was demonstrated that the hyperphagic properties of AEA and
2-AG are speciﬁcally mediated by central CB1 (Williams and
Kirkham, 1999; Kirkham et al., 2002). Besides reinforcing the
action of SR14176 on suppressing food intake in the rat, behavioral
aspects related to motivational processes in both the appeti-
tive and consummatory phases of feeding behavior are involved
(Thornton-Jones et al., 2005). Subsequently, others reported that
the CB1 receptor antagonists/inverse agonists (e.g., Rimonabant,
analog AM 251) actions on reducing food intake appears to be
linked to or mediated by behavioral aspects in the rat (Tallett
et al., 2007). Adiponectin mRNA and plasma adiponectin were
elevated in vehicle-treated chow-fed animals compared to obese
controls, and did not differ between rimonabant-treated and
pair-fed animals. The similarities between rimonabant-treated
and pair-fed animals in body weight loss and the absence of
differences in measures of adiponectin activity between drug-
treated and pair-fed animals suggest that the outcomes of this
experiment were solely mediated by the drug-induced reduc-
tion in food intake (Thornton-Jones et al., 2006). Others have
reported a reduced but transient food intake in rats treated
with a neutral CB1 receptor antagonist AM4113 (Cluny et al.,
2011). Weight control resulting in a lower food intake with
AM4113 was also observed in the rats that were subjected to
pair-feeding. With regard to sex differences and diet, Foltin and
Haney (2007) found that baboon males ate more food pellets
than females, few other sex differences were observed in this
study.
Signals to the brain from the small intestines and other organs
of the gastrointestinal system play a role in regulating energy
balance, and the ECS appears to have a role in these pathways
(Di Marzo and Matias, 2005). The interaction between the gas-
trointestinal tract and the ECS is carried out by both endocrine
and neural pathways. CB1 is present in neurons of the enteric
nervous system and in sensory terminals of vagal and spinal
neurons in the gastrointestinal tract (Massa et al., 2005). Acti-
vation of CB1 is shown to modulate nutrient processing, such as
gastric secretion, gastric emptying, and intestinal motility. Intesti-
nal derived hormones such as CCK and the adipocyte derived
hormone, leptin, decrease food intake while ghrelin has the oppo-
site effect by increasing appetite (Pagotto et al., 2006). These
hormones function as satiety and hunger signals by triggering
nerve impulses in sensory nerves that travel to the hindbrain and
hypothalamus via blood. Food intake and hunger may be under
the inﬂuence of the ECS by regulating the expression and action
of orexigenic and anorectic mediators that originated from the
hypothalamus. Leptin has also been found to lower 2-AG and
AEA levels in the hypothalamic region in rats (Di Marzo et al.,
2001). The higher levels of EC in ob/ob and db/db mice support
this observation. Remarkably, it has been reported that inactiva-
tion of CB1 results in a decrease of plasma insulin and leptin levels
(Ravinet Trillou et al., 2004). CB1 is shown to co-localize with
the food intake inhibiting neuropeptide, corticotrophin-releasing
hormone, in the paraventricular nucleus of the hypothalamus,
and with the two orexigenic peptides, melanin-concentrating hor-
mone in the lateral hypothalamus and with pre-pro-orexin in the
ventromedial hypothalamus (Inui, 1999; Horvath, 2003). CB1
knockout (KO) mice showed higher levels of CRH mRNA, sug-
gesting that hypothalamic EC receptors are involved in energy
balance and may be able to mediate food intake (Cota et al.,
2003).
The gastrointestinal tract is a site for EC production. It has been
reported that feeding inﬂuences levels of EC, such as AEA. Gomez
et al. (2002) found that after a 24-h fast, AEA levels in the small
intestine were seven times higher than that of a littermate that had
not fasted. When the ECS was blocked via antagonist (SR141716),
food intake was reduced in fasted and partially satiated rats. Thus
this work suggests that EC levels are responsive to nutrient status.
By increasing n-3 PUFA intake, the dietary ratio of n-6/n-3 PUFA
wouldbe lowered and lead to adecrease in the synthesis of AEAand
2-AG from AA. This would mimic the hormonal and behavioral
alterations that are observed in animals with treatment of a CB1
antagonist. This association between PUFA and EC supports the
premise that a lower dietary ratio of n-6/n-3 PUFA would lead to
a reduction in food intake by dietary manipulation of tissue AA
levels.
Another route where the ECS has been found to regulate food
intake is through the vagus nerve, which connects themedulla and
brainstem nuclei associated with satiety with the gastrointestinal
tract to monitor the status of digestive processes. After consuming
food, CCK is secreted from the duodenum and then binds to CCK
receptors that are located on afferent terminals of the vagus nerve.
The signal is taken up the vagal axon and to the hypothalamus
to signal the decrease of food intake. Leptin receptors have also
been found on these same nerve terminals. Reports have indicated
decreased CB1 receptor mRNA in rats that had been fed after
previously fasting or receivingCCK. In addition, in a study looking
at the effect of leptin, the investigators reported that acute leptin
treatments reduced AEA in the hypothalamus (Di Marzo et al.,
2001). The hypothalamus plays a critical role in receiving signals
from peripheral organs to inform the brain of the state of energy
status (Kirkham et al., 2002). Upon eating, wild-type rats were
observed to have reduced hypothalamic 2-AG levels compared to
when they were previously fasted.
An increase in food intake was observed when ghrelin was
infused into the paraventricular nucleus of the hypothalamus in
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rats (Tucci et al., 2004). However, when a CB1 receptor antag-
onist was added to the ghrelin treated animal, the food intake
returned to baseline. Elevated levels of the endogenous ligands,
AEA and 2-AG, have also been found in obese individuals (Engeli
et al., 2005; Osei-Hyiaman et al., 2005) and correlates with intra-
abdominal adiposity (Cote et al., 2007). Additionally, diet-induced
obese mice demonstrated higher levels of AEA and 2-AG in hip-
pocampal regions and displayed an increase inDAGL,which is one
of the enzymes responsible for the synthesis of 2-AG (Massa et al.,
2010). In the same study, ECS-mediated synaptic plasticity was
observed to have changed in the CA1 region, as depolarization-
induced suppression of inhibition and long-term depression of
inhibitory synapses were enhanced. This ﬁnding demonstrated
the potential for the ECS to remodel and inﬂuence aspects of
cognition. In another study, AEA injection into the ventromedial
hypothalamus of satiated rats induced signiﬁcant appetite stim-
ulation through CB1 receptor activation (Jamshidi and Taylor,
2001).
Although feeding a mixture of different n-3 PUFA was found
to increase plasma leptin in blood of insulin-resistant rats, food
intake did not change (Peyron-Caso et al., 2002). While leptin
functions to reduce appetite and increase energy expenditure,
resistance to leptin’s effects is well documented in metabolic com-
plications, such as obesity (Myers et al., 2010, 2012). Recently,
treatment with a CB1 inverse agonist was shown to reverse leptin
resistance and reduce obesity in diet induced obese mice (Tam
et al., 2012). In another study, both plasma insulin and lep-
tin levels were lower in CB1 KO mice, compared to wild-type
mice (Ravinet Trillou et al., 2004). Both exogenous cannabinoids
and AA-derived EC increase food intake and promote weight
gain via CB1 receptor activation (Jamshidi and Taylor, 2001;
Kirkham et al., 2002). From these studies, one can surmise that
an overactivation of the ECS is indicative of the increased adi-
posity observed with obesity. In addition, leptin status appears
to be inﬂuenced by the levels of endogenous cannabinoids, thus
validating the idea that the ECS plays a major role in energy
homeostasis. Unfortunately, the precise actions of the n-6 and n-3
families of dietary PUFA on activation of cannabinoid receptors
and their signaling downstream is not known. For this rea-
son, it is necessary to investigate how dietary PUFA inﬂuence
the ECS in order to understand food intake and macronutri-
ent metabolism and their effects on fat accretion and insulin
sensitivity.
DIETARY PUFA AND THE ENDOCANNABINOIDS
It is well recognized that dietary PUFA can alter the fatty acid
composition of glycerolipids of cells, tissues, and organs in the
body with some signiﬁcant physiological outcomes (Watkins et al.,
2006; Li et al., 2010; Hutchins-Wiese et al., 2012). In addition,
the remodeling of plasma membrane PUFA composition is well
documented in humans. Moreover, families of n-3 PUFA change
membrane phospholipid composition in most organs, including
the brain. Feeding the long chain n-3 PUFA, such as EPA and
DHA,will increase their concentrations in vivo, and to some extent
will lower the concentrations of n-6 PUFA, speciﬁcally AA. Thus,
remodeling the phospholipid composition of cell membranes and
organelles by dietary PUFA is a means to change substrate for and
the biosynthesis of prostanoids (Watkins et al., 2000), and more
recently for the biosynthesis of EC (Watkins et al., 2010; Kim and
Watkins, 2014; Kim et al., 2014a).
As suggested, tissue EC levels are responsive to substrate PUFA
availability and can be modulated by dietary levels of n-6 and
n-3 PUFA. Rodents or piglets fed diets rich in the EC sub-
strate AA showed greater 2-AG and AEA levels in the brain
(Berger et al., 2001), small intestine, and liver (Artmann et al.,
2008). Diets enriched with long chain n-3 PUFA (EPA and
DHA) decreased AA levels and resulted in lower EC levels in the
brain (Berger et al., 2001; Watanabe et al., 2003; Artmann et al.,
2008; Wood et al., 2010), small intestine, liver (Artmann et al.,
2008), visceral adipose tissue (Batetta et al., 2009), and plasma
(Wood et al., 2010). These results demonstrate the link between
dietary intake of PUFA, tissue PUFA concentrations, and EC
levels.
As described, EC are products of dietary lipids. Modiﬁcation of
dietary fat intake can modulate the EC levels, both EPA and DHA
can displace AA in cell membranes and then the derived EC, con-
sequently reducing AEA and 2-AG production (Naughton et al.,
2013). Similarly, oleoyl ethanolamide, a product of oleic acid,
induces satiety, decreases circulating fatty acid concentrations,
increases the capacity for β-oxidation, and inhibits the action of
AEA and 2-AG in adipose tissue. The dietary lipids typically higher
in n-6 PUFA drive the formation of AEA and 2-AG and likely sup-
port excessive energy intake and weight gain. Thus, understanding
how dietary fats alter ECS activity is a pertinent area of research
due to public health messages promoting a shift toward terrestrial
plant and vegetable oils.
While dietary n-3 PUFA deﬁciencies have been linked to neu-
ropsychiatric diseases (Parker et al., 2006), a potential underlying
cause may be due to the desensitization and uncoupling of CB1 in
the prelimbic prefrontal cortex and accumbens (Lafourcade et al.,
2011). Recently, consumption of n-3 PUFA was shown to abolish
negative consequences of non-functional CB1 activation regard-
ing mood and behavior. In a study using 80 Male C57/blk6 mice
(21-days-old), fed a modiﬁed AIN-93G diet (containing 11.04%
fat) and assigned to either the control diet containing safﬂower
oil or a DHA enriched diet (both diets were isocaloric and isoni-
trogenous), there were signiﬁcant changes in the concentrations
of n-3 and n-6 PUFA in tissues (serum, anterior tibialis, epididy-
mal fat pads, and liver), including the brain (Kim et al., 2014b).
After 62 days, mice fed the DHA diet had higher levels of 14:0,
16:1n7, 18:1n9, 18:2n6, 20:3n6, 22:5n3, and 22:6n3 in the brain,
compared to the mice fed the control diet (Table 1; Kim et al.,
2014b). Not surprisingly, the ratio of n-6/n-3 PUFA in the brain
was signiﬁcantly reduced in the DHA diet group, as compared to
the control group (0.71 vs. 1.26). More speciﬁcally, the ratio of
AA to DHA was reduced in the DHA diet fed mice (0.48 vs. 0.77).
As shown in Table 2, after 118 days, brains from the mice given
the DHA diet were observed to have higher levels of 14:0, 18:1n9,
18:2n6, 20:3n6, 20:5n3, 22:5n3, and 22:6n3, compared to the con-
trol diet fed mice (Kim et al., 2014b). Once again, the ratio of
n-6/n-3 PUFA in the brain was signiﬁcantly reduced in the mice
fed the DHA diet, as compared to the mice fed the control diet
(0.71 vs. 1.50). The ratio of AA to DHA was also reduced (0.48
vs. 0.86). The change in PUFA levels of the brain of mice given
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Table 1 | Mouse brain fatty acid composition after 62 days of feeding a
semi-purified diet.
FA Control DHA t -test p value
Mean SD Mean SD
12:0 ND ND
14:0 0.13 0.00 0.14 0.005 0.012
14:1n5 ND ND
15:0 ND ND
16:0 19.38 0.13 19.13 0.22 0.0076
16:1t 0.15 0.004 0.13 0.002 <0.0001
16:1n7 0.44 0.02 0.47 0.01 0.0017
17:0 0.14 0.01 0.14 0.01 0.77
18:0 19.57 0.13 19.51 0.10 0.31
18:1n9 15.14 0.12 16.06 0.21 <0.0001
18:1n7 3.79 0.07 3.46 0.05 <0.0001
18:2n6 0.79 0.08 1.20 0.11 <0.0001
18:3n6 ND ND
18:3n3 ND ND
20:0 0.35 0.01 0.34 0.02 0.067
20:1n9 1.88 0.08 1.88 0.12 0.98
20:2n6 0.23 0.03 0.23 0.02 0.94
20:3n6 0.36 0.01 0.78 0.02 <0.0001
20:4n6 9.92 0.10 8.00 0.11 <0.0001
20:5n3 ND 0.02 0.04 0.17
22:0 0.21 0.01 0.22 0.01 0.35
22:1n9 0.19 0.01 0.18 0.01 0.55
22:4n6 2.99 0.06 1.89 0.04 <0.0001
22:5n6 2.06 0.09 ND <0.0001
22:5n3 ND 0.19 0.01 <0.0001
22:6n3 12.96 0.17 16.71 0.25 <0.0001
24:0 0.25 0.02 0.26 0.02 0.16
24:1n9 0.31 0.06 0.33 0.05 0.60
TOTS 40.04 0.15 39.74 0.23 0.0047
TOTM 21.76 0.26 22.38 0.38 0.0009
PUFA 29.32 0.27 29.01 0.29 0.036
TN6 16.35 0.18 12.09 0.15 <0.0001
TN3 12.96 0.17 16.92 0.25 <0.0001
AA/DHA 0.77 0.01 0.48 0.01 <0.0001
n-6/n-3 1.26 0.02 0.71 0.01 <0.0001
Area% 91.27 0.13 91.27 0.11 0.95
Total area 4644 483 4397 397 0.25
Values areweight percentages determined by gas chromatography (Watkins et al.,
2010). N = 9 control group, and n = 9 for the DHA group. ND, not detected at the
integration condition applied on these data.
the DHA enriched diet were nearly identical to the levels found
after 62 days. These data support the premise that dietary PUFA
alter the fatty acid composition of the brain and the substrate for
the biosynthesis of EC (Wood et al., 2010; McPartland et al., 2014).
Dietary supplementationwith n-3 PUFA predictably increased the
Table 2 | Mouse brain fatty acid composition after 118 days of feeding
a semi-purified diet.
FA Control DHA t -test p value
Mean SD Mean SD
12:0 ND ND
14:0 0.12 0.003 0.13 0.003 0.017
14:1n5 ND ND
15:0 ND ND
16:0 18.87 0.28 18.90 0.19 0.76
16:1t 0.15 0.005 0.13 0.01 <0.0001
16:1n7 0.47 0.02 0.48 0.01 0.093
17:0 0.13 0.01 0.13 0.003 0.73
18:0 20.09 0.14 19.93 0.07 0.0072
18:1n9 15.51 0.21 16.52 0.17 <0.0001
18:1n7 3.83 0.13 3.45 0.02 <0.0001
18:2n6 0.75 0.08 0.95 0.07 <0.0001
18:3n6 ND ND
18:3n3 ND ND
20:0 0.34 0.03 0.31 0.01 0.024
20:1n9 2.06 0.16 2.06 0.10 0.91
20:2n6 0.19 0.01 0.20 0.02 0.74
20:3n6 0.31 0.02 0.75 0.03 <0.0001
20:4n6 9.86 0.15 7.87 0.22 <0.0001
20:5n3 ND 0.09 0.03 <0.0001
22:0 0.21 0.02 0.20 0.01 0.18
22:1n9 0.19 0.01 0.18 0.01 0.032
22:4n6 3.25 0.09 1.99 0.04 <0.0001
22:5n6 2.90 0.19 ND <0.0001
22:5n3 ND 0.20 0.01 <0.0001
22:6n3 11.51 0.24 16.29 0.24 <0.0001
24:0 0.24 0.03 0.23 0.02 0.44
24:1n9 0.40 0.05 0.36 0.06 0.20
TOTS 40.00 0.24 39.82 0.16 0.084
TOTM 22.46 0.39 23.05 0.29 0.0020
PUFA 28.77 0.39 28.33 0.32 0.017
TN6 17.26 0.26 11.75 0.18 <0.0001
TN3 11.51 0.24 16.58 0.26 <0.0001
AA/DHA 0.86 0.02 0.48 0.01 <0.0001
n-6/n-3 1.50 0.04 0.71 0.01 <0.0001
Area% 91.38 0.25 91.33 0.09 0.60
Total area 4646 256 4472 225 0.14
Values areweight percentages determined by gas chromatography (Watkins et al.,
2010). N = 9 control group, and n = 9 for the DHA group. ND, not detected at the
integration condition applied on these data.
concentration of EPA and/or DHA in tissues, cells, and plasma,
and it decreased the relative concentration of AA. However, the
data showing the effects of feeding n-3 PUFA to mice are more
complex than a simple decrease in AA and increase in n-3 PUFA,
as indicated by other aspects of their biochemistry.
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MUSCLE, LIVER, ADIPOSE AND THE ENDOCANNABINOID
SYSTEM
The primary organs of macronutrient metabolism and energy
expenditure that support growth and impact obesity and diabetes
include the gastrointestinal tract, muscle, liver, adipose, and the
endocrine system. The gastrointestinal tract is a site for the pro-
duction of EC, and alongwith its associated organs, it is inﬂuenced
by the ECSduring the digestion and absorption ofmacronutrients.
Muscle and liver are sites for glucose storage, as glycogen and adi-
pose are for fat deposition. Furthermore, biochemical pathways
of glucose, amino acids, and lipid metabolism link the muscle,
liver, and adipose to cooperatively sustain the supply of interme-
diates that maintain energy balance in the fed and fasting state,
as well as for growth and maintenance. It is clear that the ECS
is a key player in macronutrient metabolism between the organs
involved in food intake and systemic energy balance (DiMarzo and
Matias, 2005; Viveros et al., 2008; Tibirica, 2010; Kim et al., 2013).
At the gene level, sensitivity ofmuscle to insulin and glucose uptake
appears to be inﬂuenced by the ECS (Kim et al., 2014a). Aspects
of the involvement of the ECS in obesity, with speciﬁc studies in
adipocyte cell cultures and adipose tissues, are described in the
literature (Naughton et al., 2013). In many studies, the levels of
EC and the activities of enzymes of EC synthesis and degradation
suggest that a diet emphasizing n-6 PUFA, speciﬁcally AA, is a
factor of concern.
We reported that feeding DHA to mice compared to feeding
a semi-puriﬁed control diet resulted in an increase in the gene
expression of cannabinoid receptors and enzymes for the syn-
thesis/degradation of EC and for glucose metabolism (Kim et al.,
2014b). The change in expression of ECS genes also indicated
differences between muscle and adipose in mice. Furthermore,
epididymal fat mass was lower in mice fed the DHA containing
semi-puriﬁed diet, as compared to mice fed the control diet. If
the action of DHA is as the EC, docosahexaenoyl ethanolamide,
it may alter cannabinoid downstream signaling to improve glu-
cose uptake in myoblasts (Kim et al., 2014a) and in vivo, the
potential for n-3 PUFA to reduce diabetes is worthy of investi-
gation. In support of these ﬁndings and the link to macronutrient
metabolism, these initial studies in mice show that DHA, most
likely through the ECS, alters metabolite proﬁles to favor fatty acid
oxidation and reduce fat accretion (Kim et al., 2014b). Although
these are early ﬁndings, they support the premise that dietary
PUFA have roles in the ECS and eating behavior. At the least,
mechanistic research in rodent models and clinical investiga-
tions on dietary PUFA in glucose metabolism and fat accretion
are warranted to understand the relationships of fat intake and
the ECS.
High circulating levels of AA-derived EC and excessive endo-
cannabinoid production by adipocytes are associated with human
obesity and fat accretion in rodents (Engeli et al., 2005; Cote
et al., 2007). The ECS works through many anorexigenic and
orexigenic pathways where ghrelin, leptin, adiponectin, endoge-
nous opioids, and corticotropin-releasing hormones are involved
(Viveros et al., 2008). Taken together, with the emerging role
played by the ECS in obesity and with over production of the
AA-derived EC prolonging stimulation of CB1 that leads to dys-
regulation (Matias et al., 2006, 2008), there is convincing evidence
to focus future research on dietary PUFA and the ECS inmetabolic
syndrome.
Systemic macronutrient metabolism of carbohydrates, amino
acids, and fatty acids now places the ECS as a target to redi-
rect the fate of energy metabolism in the gastrointestinal tract,
liver, muscle, and adipose. The ECS is an established player in
CNS control of food intake. Emerging evidence of the phylo-
genic and developmental aspects of the ECS can be useful in
understanding this complex system (Viveros et al., 2008). This
research suggests that the genes for endocannabinoid enzymes,
especially DAGL-α and NAPE-PLD, may contain alleles that
express disease-related phenotypes, and therefore, place a greater
emphasis on fully exploring the nature of how dietary PUFA inﬂu-
ence activation of the cannabinoid receptors and downstream
signals.
CONCLUSIONS: ENDOCANNABINOIDS, EATING BEHAVIOR,
AND AGING
As described in this review, the ECS plays an important role in
eating, and speciﬁcally, when activated, CB1 leads to stimulation
of food intake, which includes the behavioral aspects observed
in fasted mice (Soria-Gomez et al., 2014). The mechanisms and
actions of the ECS in the full array of the drive to eat are not
well understood. Mechoulam and Parker (2013) recently reviewed
several behavioral aspects of the ECS in the brain, suggesting that
the brain contains numerous EC-like compounds that activate
the cannabinoid receptors to inﬂuence mood, depression, cogni-
tion, and learning; however, further study is needed to advance
the knowledge of the CNS and brain functions. Interestingly,
the distribution of the CB1 receptors, which is a primary recep-
tor in the brain (Wilson and Nicoll, 2002) and CNS, differs in
neonatal and adult brains. Moreover, since cannabinoid recep-
tor distribution and expression are inﬂuenced by aging, research
should determine how the ECS functions during aging and espe-
cially with the loss of appetite in older adults. These ﬁndings
underscore the complex nature of the ECS, which is a compre-
hensive component that ultimately impacts all aspects of eating
behavior.
It is well known that the ECS and the endogenously produced
EC are crucial components for inducing food intake and con-
trolling macronutrient metabolism (Di Marzo and Matias, 2005).
The ﬂux through metabolic pathways for glucose, fatty acids, and
amino acids is largely dependent on rate regulating enzymes of
metabolic pathways in major organs, such as muscle, liver, and
adipose, which are all impacted by the ECS. Hence, understanding
these intermediary pathways, endocrine factors, and gene expres-
sion will encourage important areas of research to determine the
role of the ECS on eating behavior (Richard et al., 2009). As previ-
ously stated, one research approach should be to characterize how
the different PUFA families integrate in the processes of metabolic
ﬂux of macronutrient pathways in major organs where the ECS is
of consequence.
In this review, we described the current research on the ECS
and food intake,macronutrient metabolism, and the participating
dietary PUFA that serve as substrate for the biosynthesis of EC. The
evidence clearly indicates that the activation of the cannabinoid
receptors in the brain stimulates food intake and overstimulation
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of theECScontributes toovereating andobesity. Thenewlydiscov-
ered feature of the ECS is that diet, speciﬁcally PUFA, inﬂuences
genes of the ECS in cells and tissues. In this regard, the ECS partic-
ipates in macronutrient metabolism and energy status in adipose
and muscle that appears to be highly dependent on the type of EC
derived from dietary PUFA. Future studies should focus on the
underlying aspects of how the n-6 and n-3 dietary PUFA fami-
lies affect the ECS, alter the types of EC synthesized, change gene
expression of the ECS, and direct the signaling pathways down-
stream of receptor activation. These investigations will potentially
impact obesity risk and metabolic syndrome.
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